{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T03:40:17Z","timestamp":1678506017200},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1991,8,1]],"date-time":"1991-08-01T00:00:00Z","timestamp":681004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1991,8,1]],"date-time":"1991-08-01T00:00:00Z","timestamp":681004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1991,8]]},"DOI":"10.1007\/bf00176977","type":"journal-article","created":{"date-parts":[[2004,8,23]],"date-time":"2004-08-23T23:20:29Z","timestamp":1093303229000},"page":"245-252","source":"Crossref","is-referenced-by-count":0,"title":["Phase I study of escalating dose mitoxantrone in combination with \u03b1-2-interferon in patients with advanced solid tumors"],"prefix":"10.1007","volume":"9","author":[{"given":"Giampietro","family":"Gasparini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Dal Fior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Pozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gino Antonio","family":"Panizzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Favretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00176977_CR1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaac","year":"1957","unstructured":"Isaac A, Lindenmann T: Virus interference \u2014 I. The Interferon. Proc R Soc Lond B Biol 147:258\u2013267, 1957","journal-title":"Proc R Soc Lond B Biol"},{"key":"BF00176977_CR2","first-page":"207","volume":"13","author":"SE Krown","year":"1986","unstructured":"Krown SE: Interferons and Interferon inducers in cancer treatment. Sem Oncol 13:207\u2013217, 1986","journal-title":"Sem Oncol"},{"key":"BF00176977_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/scientificamerican0883-36","volume":"249","author":"S Pestka","year":"1983","unstructured":"Pestka S: The purification and manufacture of human interferons. Sci Am 249:37\u201343, 1983","journal-title":"Sci Am"},{"key":"BF00176977_CR4","first-page":"789","volume":"70","author":"RK Oldham","year":"1983","unstructured":"Oldham RK: Biological response modifiers. J Natl Cancer Inst 70:789\u2013796, 1983","journal-title":"J Natl Cancer Inst"},{"key":"BF00176977_CR5","first-page":"1621","volume":"49","author":"KA Foon","year":"1989","unstructured":"Foon KA: Biological response modifiers: The new immunotherapy. Cancer Res 49:1621\u20131639, 1989","journal-title":"Cancer Res"},{"key":"BF00176977_CR6","first-page":"231","volume":"516","author":"I Gresser","year":"1978","unstructured":"Gresser I, Tovey MG: Antitumor effects of interferon. Biochem Biophys Acta 516:231\u2013247, 1978","journal-title":"Biochem Biophys Acta"},{"key":"BF00176977_CR7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ijc.2910300217","volume":"30","author":"FR Balkwill","year":"1982","unstructured":"Balkwill FR, Moodie EM, Freedman V, Fantes KH: Human Interferon inhibits the growth of established human breast tumors in nude mide. Int J Cancer 30:231\u2013235, 1982","journal-title":"Int J Cancer"},{"key":"BF00176977_CR8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/0002-9343(86)90360-8","volume":"81","author":"SM Roth","year":"1986","unstructured":"Roth SM, Foon KA: \u03b1-interferon in the treatment of hematologic malignancies. Am J Med 81:871\u2013882, 1986","journal-title":"Am J Med"},{"key":"BF00176977_CR9","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.1986.03380100016003","volume":"256","author":"B Merz","year":"1986","unstructured":"Merz B: Interferon's track record: Good in hairy-cell leukemia, fair in other hematologic cancers, poor in solid tumors. JAMA 256:1242\u20131244, 1986","journal-title":"JAMA"},{"key":"BF00176977_CR10","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.1985.3.11.1522","volume":"3","author":"JR Quesada","year":"1985","unstructured":"Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU: Antitumor activity of recombinant-derived interferon-\u03b1 in metastatic renal cell carcinoma. J Clin Oncol 3:1522\u20131528, 1985","journal-title":"J Clin Oncol"},{"key":"BF00176977_CR11","first-page":"817","volume":"69","author":"D Vugrin","year":"1985","unstructured":"Vugrin D, Hood L, Taylor W, Lazlo J: Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma. Cancer Treat Rep 69:817\u2013820, 1985","journal-title":"Cancer Treat Rep"},{"key":"BF00176977_CR12","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/1097-0142(19860415)57:8+<1675::AID-CNCR2820571307>3.0.CO;2-I","volume":"57","author":"SS Legha","year":"1986","unstructured":"Legha SS: Interferons in the treatment of malignant melanoma. A review of recent trials. Cancer 57:1675\u20131677, 1986","journal-title":"Cancer"},{"key":"BF00176977_CR13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-93-3-399","volume":"93","author":"JU Gutterman","year":"1980","unstructured":"Gutterman JU, Blumenschein GR, Alexanian R, et al.: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93:399\u2013406, 1980","journal-title":"Ann Intern Med"},{"key":"BF00176977_CR14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198307213090301","volume":"309","author":"K Oberg","year":"1983","unstructured":"Oberg K, Funa K, Alm G: Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Engl J Med 309:129\u2013133, 1983","journal-title":"N Engl J Med"},{"key":"BF00176977_CR15","first-page":"72","volume":"13","author":"DD Von Hoff","year":"1986","unstructured":"Von Hoff DD, Sarosy G, Brown TD, Kuhn JG, Kisner DL: Rationale for and conduct of a phase I clinical trial with interferon alfa-2b plus doxorubicin. Semin Oncol 13:72\u201377, 1986","journal-title":"Semin Oncol"},{"key":"BF00176977_CR16","first-page":"904","volume":"44","author":"FR Balkwill","year":"1984","unstructured":"Balkwill FR, Moodie EM: Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 44:904\u2013908, 1984","journal-title":"Cancer Res"},{"key":"BF00176977_CR17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/1097-0142(19810701)48:1<5::AID-CNCR2820480103>3.0.CO;2-C","volume":"48","author":"LM Slater","year":"1981","unstructured":"Slater LM, Welzel MW, Cesario MD: Combined interferon-antimetabolite therapy of murine L1210 leukemia. Cancer (Phila.) 48:5\u20139, 1981","journal-title":"Cancer (Phila.)"},{"key":"BF00176977_CR18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00255753","volume":"10","author":"MS Aapro","year":"1983","unstructured":"Aapro MS, Alberts DS, Slamon, SE: Interactions of human leukocyte interferon with Vinca alkloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharm 10:161\u2013166, 1983","journal-title":"Cancer Chemother Pharm"},{"key":"BF00176977_CR19","first-page":"4916","volume":"46","author":"J Carmichael","year":"1986","unstructured":"Carmichael J, Fergusson RJ, Wolf R, Balkwill FR, Smyth JF: Augmentation of cytotoxicity of chemotherapy by human interferons in human non-small cell lung cancer xenografts. Cancer Res 46:4916\u20134920, 1986","journal-title":"Cancer Res"},{"key":"BF00176977_CR20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ijc.2910350605","volume":"35","author":"CE Welander","year":"1985","unstructured":"Welander CE, Morgan TM, Homesley HD, Trotta PP, Spiegel RJ: Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 35:721\u2013729, 1985","journal-title":"Int J Cancer"},{"key":"BF00176977_CR21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.1983.1.3.217","volume":"1","author":"SE Salmon","year":"1983","unstructured":"Salmon SE, Durie BGM, Young L et al.: Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217\u2013225, 1983","journal-title":"J Clin Oncol"},{"key":"BF00176977_CR22","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0006-291X(84)90864-7","volume":"119","author":"G Soslau","year":"1984","unstructured":"Soslau G, Bogucki AR, Gillespie D: Phosphoproteins altered by antiproliferative doses of human interferon \u03b2 in a human bladder carcinoma cell line. Biochem Biophys Res Commu 119:941\u2013948, 1984","journal-title":"Biochem Biophys Res Commu"},{"key":"BF00176977_CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jnci\/80.3.151","volume":"80","author":"CR Faltynek","year":"1988","unstructured":"Faltynek CR, Oppenheim JJ: Interferons in host defence, J Natl Cancer Inst 80:151\u2013153, 1988","journal-title":"J Natl Cancer Inst"},{"key":"BF00176977_CR24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0140-6736(87)90901-9","volume":"2","author":"FR Balkwill","year":"1987","unstructured":"Balkwill FR, Smyth JR: Interferons in cancer therapy; a reappraisal. Lancet 2:317\u2013319, 1987","journal-title":"Lancet"},{"key":"BF00176977_CR25","unstructured":"Lonberg M, Odajnyk C, Kriegel R, Laubenstein L, Wernz JC, Green MD, Muggia FM: Sequential and simultaneous alpha 2 interferon (INF) and VP16 in epidemic Kaposi's sarcoma (EKS). Proc Am Soc Clin Oncol, C-8, 1985"},{"key":"BF00176977_CR26","first-page":"5368","volume":"46","author":"GA Sarosy","year":"1986","unstructured":"Sarosy GA, Brown TD, Von Hoff DD, Spiegel RJ, Golando JP, Beougher KL, Kuhn JG, Kisner DL: Phase I study of \u03b12-interferon plus doxorubicin in patients with solid tumors. Cancer Res 46:5368\u20135371, 1986","journal-title":"Cancer Res"},{"key":"BF00176977_CR27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1200\/JCO.1986.4.3.408","volume":"4","author":"ET Creagan","year":"1986","unstructured":"Creagan ET, Kovack JS, Long HJ, Richardson RL: Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer. J Clin Oncol 4:408\u2013413, 1986","journal-title":"J Clin Oncol"},{"key":"BF00176977_CR28","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0277-5379(85)90282-2","volume":"21","author":"E.O.R.T.C.","year":"1985","unstructured":"E.O.R.T.C.: New Drug Development Committee. E.O.R.T.C. guidelines for phase I trials with single agents in adults. Eur J Cancer Clin Oncol 21:1005\u20131007, 1985","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF00176977_CR29","first-page":"210","volume-title":"Cancer Clinical Trials. Methods and Practice","author":"DD Von Hoff","year":"1984","unstructured":"Von Hoff DD, Kuhn J, Clark GM: Design and conduct of phase I trials. In: ME Buyse, M Staquet, RJ Sylvester (eds.), Cancer Clinical Trials. Methods and Practice, pp. 210\u2013220. Oxford: Oxford Univ. Press, 1984"},{"key":"BF00176977_CR30","volume-title":"Handbook for Reporting Results of Cancer Treatment","author":"W.H.O.","year":"1979","unstructured":"W.H.O. Handbook for Reporting Results of Cancer Treatment. World Health Organization, publ. n\u2218 48. Geneva, W.H.O. Offset, 1979"},{"key":"BF00176977_CR31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207\u2013214, 1981","journal-title":"Cancer"},{"key":"BF00176977_CR32","first-page":"1516","volume":"40","author":"DD Von Hoff","year":"1980","unstructured":"Von Hoff DD, Polland E, Kuhn J et al.: Phase I clinical investigation of 1,4 dihydroxy-5,8-bis 2-(2-hydroxyethyl-amino)-ethyl-amino -9,10-anthracenedione dihydrochloride (NCS 301739), a new anthracenedione. Cancer Res 40: 1516\u20131518, 1980","journal-title":"Cancer Res"},{"key":"BF00176977_CR33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00292881","volume":"8","author":"N Savaray","year":"1982","unstructured":"Savaray N, Lu K, Valdivieso M et al.: Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol 8:113\u2013117, 1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00176977_CR34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jcp.1041290416","volume":"4","author":"R Oldham","year":"1986","unstructured":"Oldham R: Biotherapy: The 4th modality of cancer treatment. J Cell Physiol (Suppl.) 4:91\u201399, 1986","journal-title":"J Cell Physiol (Suppl.)"},{"key":"BF00176977_CR35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4049\/jimmunol.137.2.727","volume":"137","author":"JM Fidler","year":"1986","unstructured":"Fidler JM, De Joy SQ, Gibbons JJ Jr: Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 137:727\u2013732, 1986","journal-title":"J Immunol"},{"key":"BF00176977_CR36","series-title":"Research methods in clinical oncology","first-page":"171","volume-title":"Biologic response modifiers","year":"1988","unstructured":"Biologic response modifiers. In: BG Leventhal, RE Wittes (eds.), Research methods in clinical oncology, pp. 171\u2013190. New York: Raven Press, 1988"},{"key":"BF00176977_CR37","first-page":"2574","volume":"48","author":"MD Green","year":"1988","unstructured":"Green MD, Speyer JL, Hochster HS, Liebes LF, Dunleavy S, Widman T, Wernz JC, Blum RH, Spiegel RJ, Muggia FM: Phase I trial of escalating dose doxorubicin administered concurrently with \u03b1-interferon. Cancer Res 48:2574\u20132578, 1988","journal-title":"Cancer Res"},{"key":"BF00176977_CR38","first-page":"721","volume":"69","author":"HB Muss","year":"1985","unstructured":"Muss HB, Welander C, Caponera M, Reavis K, Cruz JM, Cooper MR, Jackson DV, Richards F, Stuart JJ, Spurr CL, White DR, Zekan PJ, Capizzi RL: Interferon and doxorubicin in renal cell carcinoma. Cancer Treat Rep 69:721\u2013722, 1985","journal-title":"Cancer Treat Rep"},{"key":"BF00176977_CR39","first-page":"5249","volume":"44","author":"FR Balkwill","year":"1984","unstructured":"Balkwill FR, Mowshowitz S, Seilman SS et al.: Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug metabolizing enzymes. Cancer Res 44:5249\u20135255, 1984","journal-title":"Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00176977.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00176977\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00176977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00176977.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T03:13:19Z","timestamp":1678504399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00176977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,8]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1991,8]]}},"alternative-id":["BF00176977"],"URL":"https:\/\/doi.org\/10.1007\/bf00176977","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,8]]}}}